Title: Competitors

Value:
in 2013  oncomed had at least two direct competitors  both public american companies  stemline therapeutics and verastem  ref name  timmerman2013    by 2014  the list of firms pursuing therapies targeting   cancer stem cell   had grown to include boston biomedical  a subsidiary of   dainippon sumitomo pharma       glaxosmithkline      astellas pharma      sanofi    the american subsidiary  and   pfizer    however  stemline and verastem remain the only two competitors solely focused cancer stem cells  ref name  de2014    one analyst holds that oncomed is the best positioned of the three companies focused the cancer stem cell area  ref name  de2014   